Table of Contents
<< Previous Issue | Dec 2016 (Vol: 2016, Issue: 12) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Novartis Exercises Option to Acquire Selexys Pharmaceuticals to Add Sickle Cell Disease Candidate
-
Grünenthal Bolsters its Pain Pipeline with Thar Acquisition
- Section: Research & Development
-
BMS Harnesses Enterome’s Microbiome Technology in Immuno-Oncology
-
Celgene acquires first asset, marizomib, from partner Triphase Accelerator
-
Committed to Amyloid Research, Lilly Expands its Collaboration with AstraZeneca